NASHVILLE, Tenn., Feb. 12, 2026 (GLOBE NEWSWIRE) — Healthcare Realty Trust Incorporated (NYSE:HR) today announced results for the fourth quarter ended December 31, 2025 and introduced full year 2026 guidance. “2025 represented a transformational year for Healthcare Realty,” commented Peter Scott, the Company’s President and Chief Executive Officer. “Our operational team delivered same-store growth that continues to exceed historical levels while our transactions team exceeded targets with $1.2 billion in dispositions at attractive pricing levels. We are encouraged by secular long-term trends driving demand for outpatient medical services, tenant space and assets across the country. We have strategically strengthened our corporate governance, leadership team and balance sheet over the past nine months, and I would like to thank...

Roadzen delivers 18.8% revenue increase and reduces operating loss by 25.4% over prior-year quarter Strategic wins, new contracts and acquisitions, expand Roadzen’s U.S. market presence and full-stack operating capabilities, reinforcing its position as a global AI leader at the intersection of insurance and mobilityYear-over-year Sequential Revenue Growth; Record Nine-Month RevenueQ3 revenue increased 18.8% over the prior-year quarter and 4.9% from Q2 to $14.4 million; nine-month revenue rose 18.3% to $38.9 million, marking a record nine months and Roadzen’s best quarter in the last two years. Operating Loss Continue to Materially Decline; Sixth Consecutive Quarter of Adjusted EBITDA1 improvementQ3 operating loss narrowed to $(2.4) million from $(3.2) million in the prior-year quarter, a 25.4% year-over-year improvement. Adjusted EBITDA...

VISTA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — Flux Power Holdings, Inc. (NASDAQ: FLUX), a leading developer of advanced lithium-ion energy storage solutions and software-driven electrification for commercial and industrial equipment, today reported financial and operational results for the 2026 fiscal second quarter ended December 31, 2025. Second Quarter and Recent Business HighlightsIncreased revenue 7.2% sequentially to $14.1 million Achieved positive GAAP net income for the first time in its history Secured more than $3.6 million in additional purchase orders to support a long-standing airline customer Awarded U.S. Patent for determining the State of Health (SoH) of a battery pack, which uses advanced algorithms for predictive diagnostics to extend the overall battery lifespan Introduced next-gen telematics hardware SkyLNK...

SEATTLE, Feb. 12, 2026 (GLOBE NEWSWIRE) — Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the fourth quarter and full year ended December 31, 2025. “Since 2021, we’ve delivered more than $500 million in discretionary profit, growing at a 22% CAGR, including over $150 million last year alone,” said Margi Tooth, Chief Executive Officer and President of Trupanion. “In 2025, we achieved our 15% annual margin target, while increasing subscription revenue and reinvesting record profits to drive four straight quarters of higher retention and accelerating gross pet adds. We’re poised to advance confidently into our next strategic plan.”Fourth Quarter 2025 Financial and Business HighlightsTotal revenue was $376.9 million, an increase of 12% compared to...

CAMPBELL, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced financial results for the fourth quarter and year ended December 31, 2025 and provided estimated first quarter and full year 2026 guidance. “In the fourth quarter of 2025, we again delivered strong financial results, including a new record of Annual Contract Value plus royalties reaching $83.6 million, representing 28% year-over-year growth. During the quarter, our customers surpassed the milestone of more than four billion systems shipped with SoCs connected by Arteris System IP, and we enjoyed royalty growth of 50% year-over-year,” said K. Charles Janac, President and CEO of Arteris. “As cybersecurity threats intensify not just in software but...

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025. Congenital Hyperinsulinism (HI)In December 2025, Rezolute reported topline results from sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI. The study did not meet its primary or key secondary endpoints.The study demonstrated reductions from baseline in hypoglycemia events by self-monitored blood glucose at both ersodetug dose levels, but reductions were not statistically significant compared to...

Company delivers 100th consecutive quarter of topline growth Fourth quarter 2025 revenue grew 13% and recurring revenue grew 14% from the fourth quarter of 2024 Announces planned retirement of Chief Financial Officer and appointment of new Chief Financial Officer Announces increase to Share Repurchase Program  MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) — SPS Commerce, Inc. (NASDAQ: SPSC), the leading intelligent supply chain network, today announced financial results for the fourth quarter and year ended December 31, 2025. Financial Highlights Fourth Quarter 2025 Financial HighlightsRevenue was $192.7 million in the fourth quarter of 2025, compared to $170.9 million in the fourth quarter of 2024, reflecting 13% growth. Recurring revenue grew 14% from the fourth quarter of 2024. Net income was $25.8 million or $0.68 per diluted...

MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results:  Q4 2025 Q4 2024 FY 2025 FY 2024Revenue (in millions) $44.6 $39.2 $160.0 $154.0Consumable revenue (in millions) $21.6 $18.8 $82.0 $70.3Instrument revenue (in millions) $17.3 $15.3 $53.8 $65.8Service and other revenue (in millions) $5.7 $5.1 $24.2 $17.9RevioTM system placements 21 23 61 97VegaTM system placements 42 7 140 7Annualized Revio pull-through per system ~$242,000 ~$240,000 ~$233,000 ~$252,000Ending cash, cash equivalents, and investments(in millions) $279.5 $389.9    Gross margin, operating expenses, net income (loss), and net income (loss) per share are reported on a GAAP and non-GAAP basis....

CLAYTON, Mo., Feb. 12, 2026 (GLOBE NEWSWIRE) — Perimeter Solutions (NYSE: PRM) (“Perimeter” or the “Company”), a leading provider of industrial products and services that support critical and complex customer missions across a range of niche applications, announced today it will release its financial results for the fourth quarter and year end 2025 on Thursday, February 26, 2026, before the market opens. The Company will host a conference call to discuss these results at 8:30 a.m. ET on the same day. The presentation will be led by CEO Haitham Khouri, CFO Kyle Sable, and Head of Investor Relations Seth Barker. The live webcast of the call can be accessed through Perimeter’s investor relations website at https://ir.perimeter-solutions.com/ and as follows: When: Thursday, February 26, 2026, at 8:30 AM (ET) Dial-in Number: 877-407-9764...

MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent HighlightsTotal revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarter U.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarter Total revenue for 2025 was $56.7 million, an increase of 10% over the prior year Active implanting centers in the U.S. grew to 252 in 2025, as compared to 223 in the prior year Initiated the BENEFIT-HF trial with first enrollments expected...